 |
April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read
April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Read
March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read
March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read
March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read
February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read
February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under
Nasdaq Listing Rule 5635(c)(4)
Read
February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read
February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Read
January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Read
January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read
January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read
December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read
December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
|
|
March 29 – April 3, 2019 - AACR Annual Meeting 2019
More
March 16-19, 2019 - Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
More
March 12, 2019 - Cowen and Company 39th Annual Health Care Conference
More
February 28, 2019 - Puma Biotechnology 4Q-2018 Financial Results Conference Call
More
February 14, 2019 - Guggenheim Healthcare Talks Idea Forum, Oncology Day
More
January 9, 2019 - JP Morgan 37th Annual Healthcare Conference
More
December 17, 2018 - Puma Biotechnology NALA Trial Update Call
More
November 14, 2018 - Credit Suisse 27th Annual Healthcare Conference
More
November 1, 2018 - Puma Biotechnology 3Q-2018 Financial Results Conference Call
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
|
